Piper Sandler Starts Quest Diagnostics (DGX) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall St set for lower open as Alphabet results reignite AI spending fears
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts DGX Hot Sheet
Price: $245.62 --0%
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 16
Rating Summary:
15 Buy, 17 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 16
Join SI Premium – FREE
Piper Sandler analyst David Westenberg initiates coverage on Quest Diagnostics (NYSE: DGX) with a Neutral rating and a price target of $145.00.
For an analyst ratings summary and ratings history on Quest Diagnostics click here. For more ratings news on Quest Diagnostics click here.
Shares of Quest Diagnostics closed at $141.92 yesterday.
You May Also Be Interested In
- Seaport Global Securities Starts Anthropic (ANT), Defers Offering Rating
- Jefferies Starts Absci Corp. (ABSI) at Buy
- H.C. Wainwright Assumes Agios Pharma (AGIO) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
